BRAZIL Trends and Developments Contributed by: Bruna Rocha, Jessica Filka, Juliana Marcondes and Victoria Cristofaro, COSRO
2026 as a Year of Convergence In February 2026, Brazil’s life sciences and health- care sector entered a year defined less by sweeping regulatory overhauls and more by the convergence of multiple policy and market vectors operating on different timelines. The National Health Surveillance Agency ( Agência Nacional de Vigilância Sanitária – ANVISA) and the National Supplementary Health Agency ( Agência Nacional de Saúde Suplementar – ANS) are executing forward‑looking regulatory agen- das, the Pharmaceutical Market Regulation Chamber ( Câmara de Regulação do Mercado de Medicamento s – CMED) has adopted a new pricing framework with near‑term effect, a concentrated patent cliff is reshaping competitive windows, and industrial policy instruments tied to the Unified Health System ( Sis- tema Único de Saúde – SUS) are deepening their role in how scale is financed and delivered. The implication for companies is practical and immediate: decisions about regulatory sequencing, pricing and access, supply chains and financing are no longer siloed, and misalignment in any one dimension can erode value quickly across the others. Convergence as the organising theme for 2026 The central dynamic for 2026 is convergence rath- er than transformation. Brazil is not embarking on a wholesale rewrite of its life sciences regulatory archi- tecture. Instead, regulators are consolidating reforms and selectively recalibrating sensitive regimes in ways that raise execution thresholds. From a busi- ness standpoint, this signals continuity with greater discipline rather than regulatory looseness. At the same time, global pressures, including pricing ero- sion, loss of exclusivity, geopolitical uncertainty and supply‑chain realignment, intersect with domestic policy priorities focused on access, industrial capac- ity, and public financing. That intersection materially changes how strategy must be made and sequenced. Regulatory submissions can no longer be treated as isolated milestones. Market access planning must be integrated early with pricing rules, exposure to court‑ordered access pathways known in Brazil as judicialisation and public procurement dynamics. Manufacturing and sourcing choices increasingly need to internalise trade facilitation measures, cus- toms modernisation, and cross‑border compliance
requirements. Financing and investment decisions are now closely tethered to governance, transparency and delivery capacity, particularly where SUS‑linked fund- ing or industrial policy instruments are involved. Early market signals in 2026 suggest that companies treat- ing Brazil and Latin America as an integrated portfo- lio, rather than a sequence of standalone launches, will better manage volatility and capture opportunity, whether defending value through loss of exclusivity or A persistent confidence gap characterises the global context. Many biopharma and medtech executives report optimism about their own organisations’ out- looks for 2026 while expressing lower confidence in the broader economy. That divergence reflects the need to reconcile internal momentum, including pipelines and investment in digital health and AI, with external uncertainty driven by trade realignment and sustained pricing pressure. In Brazil, this environment amplifies the premium on local adaptability. Compa- nies must tailor global approaches to Brazilian regu- latory, pricing and access realities, moving beyond assumptions of linear replication across markets. Variation across Latin America in policy execution and reimbursement dynamics further increases the value of diversified exposure, agile operating models and robust local partnerships as drivers of durable growth. Trade signalling, China and EU–Mercosur International trade signalling will remain salient in 2026. Brazil’s federal executive continues to identify market opening and strategic partnerships as priori- ties, including references to China as a key counter- part and renewed movement on the EU-Mercosur agreement alongside engagement with the European Free Trade Association. For life sciences, the commer- cial relevance lies not in diplomacy headlines but in the operational spillovers. Sourcing models, customs treatment and tariff profiles can tilt cost structures, timelines, inventory strategies and working capital, especially for companies dependent on imported active pharmaceutical ingredients, intermediates and specialised equipment. China’s deepening role as a hub for R&D, clinical development and manufactur- ing has practical implications for development time- lines, competitive entry and cross‑jurisdictional co- scaling in generics and biosimilars. Global context and local adaptation
54 CHAMBERS.COM
Powered by FlippingBook